Factors associated with D-dimer levels in HIV-infected individuals

Alvaro H Borges1, Jemma L O'Connor2, Andrew N Phillips2

  • 1Centre for Health & Infectious Diseases Research (CHIP), Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Plos One
|March 15, 2014
PubMed

Insights

Plasma D-dimer levels are elevated in women and increase with age in men with HIV. Factors like inflammation, HIV RNA, and hepatic fibrosis are associated with higher D-dimer, while CD4+ counts and HDL cholesterol are linked to lower levels.

Area of Science:

  • Biomedical Research
  • Infectious Diseases
  • Hematology

Background:

  • Higher plasma D-dimer levels are significant predictors of mortality in individuals with HIV.
  • Factors influencing D-dimer levels during HIV infection are not well understood.

Purpose of the Study:

  • To identify factors associated with plasma D-dimer levels in a large cohort of HIV-positive individuals.

Main Methods:

  • Cross-sectional study of 9,848 participants from randomized controlled trials with measured D-dimer.
  • Linear regression analysis was used to identify associated factors.
  • Investigated covariates included demographics, HIV disease markers, inflammation, ART use, comorbidities, and renal/lipid profiles.

Main Results:

  • Women had higher D-dimer levels than men; D-dimer increased more steeply with age in men.
  • Hepatitis B/C co-infection was associated with higher D-dimer, specifically linked to hepatic fibrosis (hyaluronic acid levels), not viral load.
  • Independently associated factors for higher D-dimer included black race, higher HIV RNA, not being on ART, and elevated CRP, IL-6, and cystatin C.
  • Higher baseline CD4+ counts and HDL cholesterol were negatively correlated with D-dimer.

Conclusions:

  • D-dimer levels rise with age in HIV+ men but are elevated in women early on, irrespective of comorbidities.
  • Hepatic fibrosis, not hepatitis viral load, is linked to elevated D-dimer in co-infected individuals.
Abstract

Related Concept Videos

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
469
Factors Affecting the Risk of Infection01:26

Factors Affecting the Risk of Infection

The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
14.1K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.7K